Total Number of Communication Reports: 0
Monthly communication reports in the last 6 months: 0
Subject matters | Details | Categories |
---|---|---|
Science and Technology
|
BioVectra received funding in year to support the expansion of existing technologies in biomanufacturing and mRNA/pDNA vaccine production totaling $22.8M. The total commitment of the funding awarded from the Strategic Innovation Fund (SIF) relating to this project spanning 2022-2024 was $46.5M, the residual amount is expected to be disbursed in fiscal year 2024. This funding agreement was in the form of grant and non-interest bearing repayable loan. BioVectra also sought and secured funding from provincial government in PEI to support capital investment, labor cost and other operational costs associated with the biomanufacturing and mRNA/pDNA production. Those funding agreements came in the form of non-repayable grants totaling $10M and tax incentives, of which $3.3M was received during 2023 fiscal year and the residual is expected over years 2024-2030.
|
Grant, Contribution or Other Financial Benefit
|
BioVectra is a contract development and manufacturing organization (CDMO) that serves pharmaceutical and biotech companies with full-service Current Good Manufacturing Practice (cGMP) outsourcing solutions for intermediates and active pharmaceutical ingredients (APIs).
Oliver Technow, Chief Executive Officer
End date of the last completed financial year: 2023-12-31
Government Institution | Funding Received in Last Financial Year | Funding Expected in Current Financial Year |
---|---|---|
BioTalent | $165,867.75 | Yes |
Innovation PEI | $3,254,327.69 | Yes |
Labor Market Development Program -Skills PEI | $11,714.50 | Yes |
Strategic Innovation Fund | $19,561,585.89 | Yes |
Address:
11 Aviation Avenue
Charlottetown, PE C1E 0A1
Canada
Telephone number:
902-566-9116
Fax number:
902-628-2045
BioVectra Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking